Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917366 | 0.85 | CDC25B (0.56) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL1542903 | 0.85 | CDC25B (0.56) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL1151720 | 0.85 | CDC25B (0.56) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL1152475 | 0.83 | MAPT (0.51) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL9857346 | 0.80 | APAF1 (0.54) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL1152737 | 0.80 | MAPT (0.44) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL8444855 | 0.80 | CDC25B (0.45) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL8136452 | 0.80 | MAPT (0.51) | MAPTMEN1KMT2ATP53USP2 | |
| SCHEMBL9857552 | 0.80 | MAPT (0.62) | MAPTMEN1KMT2ATP53USP2 | |
| Parvaquone SCHEMBL916441 | 0.79 | APAF1 (0.52) | MAPTMEN1KMT2ATP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-5175319-A | Antiprotozoa agent, useful for treating malaria, theileriosis, coccidiosis and prophylaxix | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5053432-A | Antiprotozoa agents; treatment of malaria | BURROUGHS WELLCOME CO. (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0123238-B1 | NAPHTHOQUINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-06-10 | — | — | EP | disclosed |
| EP-0123238-A2 | Naphthoquinone derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | MAPT 1583/4885MEN1 3612/4885KMT2A 3886/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | MAPT 1583/4885MEN1 3612/4885KMT2A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.